Case report of capecitabine toxicity and use of uridine triacetate.

Author: DuffyAlison P, HausnerPetr F, OliverWesley D

Paper Details 
Original Abstract of the Article :
Fluorouracil and capecitabine are fluoropyrimidine chemotherapy agents that are commonly used for various cancers. These agents are generally well tolerated at standard doses; however, it has been reported that 31-34% of patients develop dose-limiting toxicities. Dihydropyrimidine dehydrogenase and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/1078155217730662

データ提供:米国国立医学図書館(NLM)

Capecitabine Toxicity and Uridine Triacetate: A Case Study in the Desert of Cancer Treatment

The treatment of cancer is often a challenging journey, like navigating a vast and unforgiving desert. This case report delves into the complexities of capecitabine toxicity and the use of uridine triacetate as a potential treatment. The researchers, like experienced explorers, present a detailed account of a patient who experienced capecitabine toxicity, highlighting the need for careful monitoring and timely interventions. The case report also explores the challenges of using uridine triacetate, emphasizing the importance of individualized approaches and ongoing research in this area.

Uridine Triacetate: A Potential Oasis in the Desert of Toxicity?

The case report highlights the potential benefits of uridine triacetate in treating capecitabine toxicity. However, the researchers acknowledge that this treatment is not always effective. This reinforces the need for ongoing research to optimize the use of uridine triacetate and develop more effective strategies for managing capecitabine toxicity. It’s like searching for the most effective antidote in a desert of potential solutions.

Navigating the Desert of Cancer Treatment: Toxicity and Treatment

This case report serves as a valuable reminder of the challenges faced by patients undergoing cancer treatment. It highlights the importance of close monitoring for potential toxicities, the need for timely interventions, and the ongoing search for effective therapies. This research, like a beacon in a desert, provides valuable insights into the complexities of cancer treatment and the ongoing quest for better solutions.

Dr. Camel's Conclusion

This case report explores the challenges of capecitabine toxicity and the potential use of uridine triacetate as a treatment option. The research highlights the need for careful monitoring, timely interventions, and ongoing research to optimize treatment approaches in the complex and often unforgiving desert of cancer treatment.

Date :
  1. Date Completed 2020-06-10
  2. Date Revised 2020-06-10
Further Info :

Pubmed ID

28942723

DOI: Digital Object Identifier

10.1177/1078155217730662

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.